The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback